We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CTTH's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology... CTTH's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in major markets such as pain management. The Oral Thin Film (Wafer) formulation is protected by 3 Canadian, 2 U.S. patents and over 59 patents pending or granted worldwide. Show more
Live at MJAC 2017 Saturday 2nd September - 4.05 PM on Streaming Stage F How venture capital and cryptocurrency are converging as the future of cannabis investing ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0029 | -5.75396825397 | 0.0504 | 0.0699 | 0.041 | 3902 | 0.06912436 | CS |
4 | -0.00496 | -9.45482272207 | 0.05246 | 0.07 | 0.033 | 30672 | 0.06461207 | CS |
12 | -0.0105 | -18.1034482759 | 0.058 | 0.1 | 0.025 | 17286 | 0.06358264 | CS |
26 | 0.0175 | 58.3333333333 | 0.03 | 0.1 | 0.018 | 14755 | 0.06304197 | CS |
52 | 0.00845 | 21.6389244558 | 0.03905 | 0.1 | 0.01 | 19979 | 0.04083406 | CS |
156 | -0.0024 | -4.80961923848 | 0.0499 | 0.1 | 0.003 | 29305 | 0.0370089 | CS |
260 | -0.116755 | -71.0815500289 | 0.164255 | 0.26 | 0.003 | 24998 | 0.05742586 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions